INTRODUCTION {#s1}
============

Somatic missense mutations in histone H3 genes have been identified as recurrent events in a subset of pediatric high-grade gliomas, and less commonly found in soft tissue and bone tumors. Lysine 36-to-methionine (K36M) mutations in *H3F3B* have been found in the majority of chondroblastomas ([@MCS004606SNUC2]), and more recently, H3 mutations at lysine 36 have also been identified in two children with undifferentiated sarcomas: a *HIST1H3C* K36M and a *HIST1H3B* K36I mutation ([@MCS004606SNUC6]). The histone 3.3 K36M mutation impairs mesenchymal differentiation and has been shown to generate undifferentiated sarcomas in vivo through epigenetic reprogramming ([@MCS004606SNUC3]; [@MCS004606SNUC6]). H3K36M/I mutations lead to the reduction of H3K36 methylation and a simultaneous genome-wide gain in H3K27 methylation, resulting in a redistribution of Polycomb repressive complex 1 (PRC1) and derepression of PRC1 target genes associated with the blocking of mesenchymal differentiation.

RESULTS {#s2}
=======

Clinical Presentation, Family History, and Pathology {#s2a}
----------------------------------------------------

A 13-yr-old African--American female, with an unremarkable past medical history except for sickle cell trait, presented with a 2-wk history of recurrent progressive headaches, nausea, and vomiting. Physical examination revealed a palpable mass involving her right parietal scalp. Family history was negative for cancer and heritable disorders.

Magnetic resonance imaging (MRI) of the head with and without contrast revealed a homogeneously enhancing mass centered in the right parietal bone, with extracranial and intracranial components and associated mass effect on the parietal lobe ([Fig. 1](#MCS004606SNUF1){ref-type="fig"}). A diagnostic skeletal survey was negative for any additional bony lesions.

![Initial imaging studies. (*Left*) Sagittal and (*right*) coronal contrast-enhanced, T1-weighted MR images of the head obtained at initial diagnosis, showing a homogeneously enhancing mass centered in the right parietal bone, with extracalvarial and intracranial components and associated mass effect on the parietal lobe.](MCS004606Snu_F1){#MCS004606SNUF1}

An open biopsy of the skull lesion revealed an atypical histiocytic proliferation with associated T-cell infiltrate that appeared consistent with histiocytosis, although not Langerhans cell histiocytosis ([Fig. 2](#MCS004606SNUF2){ref-type="fig"}). The lesion was composed predominantly of histiocytes that were strongly positive for CD163 and weakly positive for CD68, but negative for S100 and CD1a. The CD45-positive lymphocytic population included a CD3-positive T-cell infiltrate. A CD20- and CD79a-positive B-cell population represented only a minority of the lesion. Hematological markers ALK-1 (anaplastic lymphoma kinase), CD15, CD30, BCL-2, BCL-6, OCT-2, and PAX-5 were negative by immunohistochemistry. The tumor was negative for EBV-encoded RNA (EBER) by in situ hybridization. Soft tissue neoplasm markers α smooth muscle actin (SMA), desmin, and caldesmon were also negative. Flow cytometric analysis with a comprehensive panel of leukemia/lymphoma markers was nondiagnostic. The Ki-67 proliferation index ranged widely between various areas of the tumor, from \<5% to 30% focally, with the marked inflammatory cell infiltrate component rendering it difficult to estimate the tumor cell proliferation rate.

![Tumor histology and immunohistochemistry. (*A*) Hematoxylin & eosin stain showing lymphohistiocytic neoplasm with (*B*) rich CD3-positive T-cell infiltrate and (*C*) CD163 positivity. (*D*) Cells show overall preserved H3K36me3 in both tumor and inflammatory cells. (*E*,*F*) In contrast, loss of H3K36me2 staining is observed in large histiocytic cells, whereas infiltrating small T cells show preserved expression. Scale bars, 100 µm.](MCS004606Snu_F2){#MCS004606SNUF2}

Given the diagnostic uncertainty, a second, larger excisional biopsy was subsequently performed, and an atypical lymphohistiocytic lesion was again identified. Immunohistochemically, the atypical cells continued to be positive for AE1/AE3 (focal), vimentin, and Ki-67 (with low to moderate proliferative rate similar to the original biopsy) and negative for CD31, CD4, CD163, CD68, CD34, CD33, Factor XIIIa, CD15, CD30, CD21, CD20, CD3, Lysozyme, CD1a, S100, ALK, MPO, FLI-1, SMA, and EBV (EBER in situ hybridization).

In light of these findings, a diagnosis of Erdheim--Chester disease (ECD) was favored. The pathology was subsequently reviewed by several outside expert hematopathology and soft tissue pathology consultants, with diagnostic impressions including a nonneoplastic reactive process and malignant neoplasms including non-Langerhans cell histiocytosis, histiocytic sarcoma, and inflammatory fibrosarcoma.

Genomic and Immunohistochemistry Analysis {#s2b}
-----------------------------------------

Whole-exome sequencing (WES) of the tumor and matched germline identified 20 somatic nonsynonymous single-nucleotide variants (SNVs) and two insertions, a frameshift insertion involving SGSM1 and a nonframe insertion involving FAM194A ([Table 1](#MCS004606SNUTB1){ref-type="table"}). We identified a somatic mutation in *HIST1H3B* with an allele frequency of 20%, leading to a K36I amino acid substitution ([Fig. 3](#MCS004606SNUF3){ref-type="fig"}). No gene fusions were identified by targeted heme and solid RNA-seq fusion panels. Immunohistochemistry for histone H3K36me2 showed decreased staining in large CD163^+^ tumor cells ([Fig. 2](#MCS004606SNUF2){ref-type="fig"}) compared to the reactive T cells' inflammatory infiltrate where H3K36me2 expression was preserved.

![Whole-exome sequencing. Comparison of the patient\'s tumor and germline DNA shows somatic *HIST1H3B* K36I single-nucleotide mutation with an estimated variant allele frequency of 13%.](MCS004606Snu_F3){#MCS004606SNUF3}

###### 

Somatic nonsynonymous mutations identified in the tumor

  Gene             Chr.        HGVS DNA reference       HGVS protein reference   Variant type       Predicted effect      dbSNP   Genotype           Tumor depth   VAF (%)
  ---------------- ----------- ------------------------ ------------------------ -------------- ------------------------- ------- ------------------ ------------- ---------
  *ANXA9*          Chr 1       c.C743T                  p.A248V                  Exonic             Nonsynonymous SNV             Heterozygous       314           10
  *FAM189B*        Chr 1       c.G446A                  p.G149E                  Exonic             Nonsynonymous SNV             Heterozygous       290           19
  *WRAP73*         Chr 1       c.C319T                  p.L107F                  Exonic             Nonsynonymous SNV             Heterozygous       115           20
  *ZCCHC11*        Chr 1       c.C4286T                 p.P1429L                 Exonic             Nonsynonymous SNV             Heterozygous       234           18
  *KNDC1*          Chr 10      c.C1708T                 p.R570W                  Exonic             Nonsynonymous SNV             Heterozygous       156           21
  *KIRREL3*        Chr 11      c.C1468T                 p.R490W                  Exonic             nonsynonymous SNV             Heterozygous       238           23
  *PTPRQ*          Chr 12      c.G4597A                 p.V1533I                 Exonic             Nonsynonymous SNV             Heterozygous       205           18
  IRG1             Chr 13      c.G1384A                 p.V462I                  Exonic             Nonsynonymous SNV             Heterozygous       196           20
  *COPS2*          Chr 15      c.G196A                  p.E66K                   Exonic             Nonsynonymous SNV             Heterozygous       374           16
  *CNGB1*          Chr 16      c.G2540A                 p.G847E                  Exonic             Nonsynonymous SNV             Heterozygous       283           18
  *KRT39*          Chr 17      c.T245A                  p.L82Q                   Exonic             Nonsynonymous SNV             Heterozygous       268           18
  *ABCA10*         Chr 17      c.T6A                    p.N2K                    Exonic             Nonsynonymous SNV             Heterozygous       332           18
  *LOXHD1*         Chr 18      c.G1594A                 p.D532N                  Exonic             Nonsynonymous SNV             Heterozygous       242           17
  *FOXD4L1*        Chr 2       c.G61A                   p.D21N                   Exonic             Nonsynonymous SNV             Heterozygous       619           17
  *DNMT3B*         Chr 20      c.G389A                  p.R130H                  Exonic             Nonsynonymous SNV             Heterozygous       281           19
  *UBE2E2*         Chr 3       c.A86C                   p.Q29P                   Exonic             Nonsynonymous SNV             Heterozygous       190           16
  *ADAMTS19*       Chr 5       c.A2603C                 p.K868T                  Exonic             Nonsynonymous SNV             Heterozygous       245           21
  *AK9*            Chr 6       c.C2594G                 p.T865S                  Exonic             Nonsynonymous SNV             Heterozygous       194           16
  ***HIST1H3B***   **Chr 6**   **c.A110T**              **p.K36I**               **Exonic**       **Nonsynonymous SNV**           **Heterozygous**   **138**       **20**
  *PRSS16*         Chr 6       c.G367A                  p.G123S                  Exonic             Nonsynonymous SNV             Heterozygous       157           27
  *SGSM1*          Chr 22      c.1130_1131insC          p.D377fs                 Exonic           Frameshift insertion            Heterozygous       128           10
  *FAM194A*        Chr 3       c.163_164insAG GAGGAGG   p.V55delinsEEEV          Exonic          Nonframeshift insertion          Heterozygous       145           23

(SNV) Single-nucleotide variant.

Treatment Outcome {#s3a}
-----------------

After the second biopsy, treatment for presumed ECD with oral prednisone and intravenous cladribine was initiated ([@MCS004606SNUC8]). No response was observed and the patient developed locally progressive disease within the first two cycles of therapy (8 wk). Treatment was then changed to anakinra (interleukin 1 receptor antagonist) injections 100 mg subcutaneously once daily ([@MCS004606SNUC1]). Anakinra was discontinued after 4 wk as a result of further disease progression, including the development of tumor-associated cerebral edema and papilledema. She subsequently underwent a radical, but subtotal resection of the skull mass. Intraoperatively, extensive bony and dural tumor involvement and invasion of the pial surface were evident.

A repeat PET/CT performed after recovery from surgery revealed widely disseminated disease with new avidly metabolic lesions involving the sternum, iliac bone, sacrum, and femur in addition to residual disease at the surgical site. Subsequently, clofarabine was initiated as salvage therapy ([@MCS004606SNUC10]) at 30 mg/m^2^/d for 5 d every 4 wk. After two treatment cycles, the disease progressed further, with increased hypermetabolic activity at the craniotomy site and known metastatic sites, as well as the appearance of new hypermetabolic lung nodules.

Given the lack of response to treatment regimens for histiocytosis/ECD and clinical behavior similar to an aggressive sarcoma, empiric chemotherapy with doxorubicin 75 mg/m²/cycle and ifosfamide 9 g/m²/cycle was initiated ([@MCS004606SNUC9]). This treatment led to an exceptional response, with near-disappearance of all PET avid metastatic lesions after two cycles of therapy ([Fig. 4](#MCS004606SNUF4){ref-type="fig"}). After two additional treatment cycles with ifosfamide, involved field external beam radiation therapy was administered to the primary site, with 5580 cGy given in 31 fractions, and two additional cycles of chemotherapy with ifosfamide and doxorubicin were administered subsequently. The patient currently remains in complete disease remission for more than 5 years.

![Disease progression and tumor response. (*A*) PET/CT revealing widely metastatic tumor dissemination after 6 mo of initial therapy, with hypermetabolic lesions including the primary site as well as sternum, iliac bone, sacrum, and femur (arrows). (*B*) Dramatic treatment response after two cycles of chemotherapy with doxorubicin and ifosfamide, with PET/CT showing near-resolution of hypermetabolic lesions.](MCS004606Snu_F4){#MCS004606SNUF4}

DISCUSSION {#s4}
==========

We report a diagnostically challenging tumor with histiocytic morphology harboring a *HIST1H3B* K36I mutation that did not respond to multiple histiocytosis regimens but had an excellent response to a chemotherapy and radiation therapy regimen used for soft tissue sarcomas.

The differential diagnosis in this patient was wide-ranging and comprised both benign and malignant disease processes including non-Langerhans cell histiocytosis, histiocytic sarcoma, and inflammatory fibrosarcoma. ECD is a rare non-Langerhans cell histiocytosis with multiorgan involvement and broad clinical features ([@MCS004606SNUC7]). Diffuse histiocytic infiltration consisting of CD68-positive and CD1a-negative lipid-laden histocytes are the traditional histological hallmarks of ECD, and a high prevalence of somatic BRAF mutations ([@MCS004606SNUC4]) has also recently been identified in this disease. ECD was initially favored in this patient based on the presence of foamy histiocytes, rare Touton-like giant cells, factor XIII positivity, lymphocytic aggregates, fibrosis, and ultrastructural features. ECD is extremely rare in children, with few cases reported to date; and the histocytic lesions are most commonly located in the long bones of the lower extremities. ECD with cranial involvement is exceedingly rare ([@MCS004606SNUC5]), and our patient did not respond to therapies previously shown to be effective in ECD.

Histiocytic sarcoma (HS) was included in the initial differential diagnosis. This rare malignant tumor of histiocytic origin is thought to arise from the monocyte/macrophage lineage and is rarely seen in children ([@MCS004606SNUC12]). The malignant cells in histiocytic sarcoma are typically positive for CD163, CD68, and lysozyme and negative for CD1a; and our patient\'s tumor also lacked characteristic histological features of histiocytic sarcoma, such as the diffuse noncohesive proliferation of large pleomorphic cells with multinucleated forms.

Whole-exome sequencing of our patient\'s tumor revealed a single oncogenic driver alteration (i.e., a *HIST1H3B* K36I mutation) leading to a global reduction in H3K36me2 expression. This finding is in line with prior studies indicating that H3K36M/I mutations lead to a global reduction in H3K36me2 ([@MCS004606SNUC3]; [@MCS004606SNUC6]). To our knowledge only a single pediatric cancer patient harboring a H3K36I has previously been described, an undifferentiated thoracic sarcoma occurring in a young child ([@MCS004606SNUC6]). No data on treatment modalities and outcome has been reported in pediatric patients with H3K36M/I-mutant sarcomas. Of note, the tumor described in this report was devoid of genomic alterations in pathways frequently altered in sarcomas and associated with aggressive behavior, such as p16, p53, and RB. At present, no data exist to link the presence of a H3K36M/I mutation to responsiveness to chemotherapy. Our report expands the histological spectrum of H3K36M/I-mutant soft tissue malignancies to histiocytic neoplasms, indicating that multiagent chemotherapy can be highly effective even in the setting of widely disseminated metastatic disease.

METHODS {#s5}
=======

We performed WES of the patient\'s tumor and matched germline DNA, as previously described ([@MCS004606SNUC11]). In brief, DNA was extracted from 10 unstained 10-µm FFPE sections using automated DNA extraction Maxwell RSC DNA FFPE (Promega). Two hundred and fifty nanograms of DNA from each sample were sheared on a Covaris instrument for 360 sec (duty cycle---10%; intensity---5; cycles/burst---200). Barcoded libraries were prepared using the Kapa Low-Throughput Library Preparation Kit Standard (Kapa Biosystems), amplified using the KAPA HiFi Library Amplification kit (Kapa Biosystems) (eight cycles), and quantified using Qubit Fluorimetric Quantitation (Invitrogen) and Agilent Bioanalyzer. An equimolar pool of the four barcoded libraries (300 ng each) were used as input to capture the exome using one reaction tube of the NimbleGen SeqCap EZ Human Exome Library v3.0 (Roche, cat \# 06465684001), according to the manufacturer\'s protocol. The pooled capture library was quantified by Qubit (Invitrogen) and Bioanalyzer (Agilent) and sequenced on an Illumina HiSeq 2500 using a paired-end, 100 nt in length run mode. The coverage was normalized by HaplotypeCaller (GATK) and the variants were called independently for each sample using MuTect2 with coverage \>100× and \>10% variant allele frequency (VAF) in tumors and \<1% in the matched normal DNA. Resulting filtered variants were annotated using ANNOVAR RefSeq hg19. Synonymous and noncoding variants were excluded.

To assess for the presence of additional oncogenic drivers including gene fusions that may have been missed by WES, we analyzed the tumors using the MSK-Solid Fusion Assay, an RNA-based targeted sequencing panel that utilizes the Archer Anchored Multiplex PCR (AMPTM) technology and next-generation sequencing to detect gene fusions in hematologic and solid tumor samples ([@MCS004606SNUC13]). The Archer custom heme and solid tumor panels were designed to target 200 and 62 specific genes, respectively, known to be recurrently involved in gene rearrangements. The complete gene list is provided in [Table 2](#MCS004606SNUTB2){ref-type="table"}.

###### 

The Archer custom heme and solid tumor panel were designed to target 200 and 62 specific genes, respectively, known to be recurrently involved in gene rearrangements

  ----------------- ----------- ----------- ----------- ------------ ----------- ----------- ------------ ------------- -------------
  Archer Pan Heme                                                                                                       
  *ABL1\**          *BTK*       *CHD1*      *EBF1*      *HOXA10*     *KLF2*      *MYBL1*     *PAX5*       *PYRY8*       *SOX11*
  *ABL2*            *CALR*      *CHIC2*     *EIF4A1*    *HOXA9*      *KMT2A\**   *MYC*       *PBX1*       *RAB29*       *SRSF2*
  *AICDA*           *CARD11*    *CIITA*     *ENTPD1*    *ID4*        *KRAS*      *MYD88*     *PDCD1*      *RAG1*        *STAT3*
  *AKT3*            *CBFB\**    *CREB3L2*   *EPOR*      *IDH1*       *LIMD1*     *MYH11*     *PDCD1LG2*   *RAG2*        *STAT5B*
  *ALK*             *CBL*       *CREBBP*    *ERG*       *IDH2*       *LMO1*      *NEK6*      *PDGFRA*     *RANBP1*      *STAT6*
  *ASB13*           *CCDC50*    *CRLF2*     *ETV6\**    *IKZF1*      *LM02*      *NF1*       *PDGFRB*     *RARA\**      *STIL*
  *ASXL1*           *CCND1*     *CSF1R*     *EXOC2*     *IKZF2*      *LRMP*      *NFKB1*     *PHF6*       *RBM15*       *STRBP*
  *BATF3*           *CCND2*     *CSF3R*     *EZH2*      *IKZF3*      *LYL1*      *NFKB2*     *PICALM*     *RHOA*        *TAL1*
  *BAX*             *CCND3*     *CTLA4*     *FAM216A*   *IL16*       *LZTS1*     *NME1*      *PIMI*       *ROSI*        *TCF3*
  *BCL11B*          *CD274*     *CYB5R2*    *FBXW7*     *IL7R*       *MAL*       *NOTCH1*    *PIM2*       *RUNX1\**     *TFG*
  *BCL2*            *CD44*      *DCK*       *FGFR1*     *IRF4*       *MALTI*     *NOTCH2*    *PLCG1*      *RUNX1T1\**   *TLX1*
  *BCL2A1*          *CD79B*     *DEK*       *FGFR2*     *IRF8*       *MAML3*     *NPM1*      *PLCG2*      *S1PR2*       *TLX3*
  *BCL3*            *CDC25A*    *DENND3*    *FGFR3*     *ITPKB*      *MECOM*     *NRAS*      *PML\**      *SEMA6A*      *TNFRSF13B*
  *BCL6\**          *CDK6*      *DLEU1*     *FLT3*      *JAK1*       *MKL1*      *NT5C2*     *PPAT*       *SERPINA9*    *TNFSF4*
  *BCR\**           *CDKN2A*    *DNM2*      *FOXP1*     *JAK2*       *MLF1*      *NTRK3*     *PRDM16*     *SETBP1*      *TP63*
  *BIRC3*           *CDKN2B*    *DNMT3A*    *FUT8*      *JAK3*       *MLLT10*    *NUP214*    *PRKAR2B*    *SETD2*       *TYK2*
  *BLNK*            *CEBPA*     *DNMT3B*    *GATA1*     *KAT6A*      *MLLT4*     *NUP98*     *PTK2B*      *SF3B1*       *U2AF1*
  *BMF*             *CEBPD*     *DNTT*      *GATA2*     *KDM6A*      *MME*       *P2RY8*     *PTPN1*      *SH2B3*       *WT1*
  *BMP7*            *CEBPE*     *DUSP22*    *GLIS2*     *KIAA0101*   *MPL*       *PAG1*      *PTPN11*     *SH3BP5*      *XPO1*
  *BRAF*            *CEBPG*     *E2F2*      *GNAS*      *KIT*        *MUC1*      *PAICS*     *PYCR1*      *SLC29A1*     *ZCCHC7*
  Archer Solid                                                                                                          
  *ALK\**           *EGFR*      *FGFR\**    *JAZF1*     *NCOA1*      *NTRK3\**   *RET\**     *TFE3\**                   
  *BCOR*            *EPC1*      *FOSB*      *KIT*       *NCOA2*      *PDGFB*     *ROS1\**    *TFEB*                     
  *BRAF\**          *ERBB2*     *FOXO1\**   *MAML2*     *NOTCH1*     *PDGFRA*    *RSP02*     *TFG*                      
  *CAMTA1*          *ERG\**     *FUS*       *MEAF6*     *NOTCH2*     *PHF1*      *RSP03*     *TMPRSS2*                  
  *CCNB3*           *ETV6*      *GLI1*      *MET*       *NR4A3*      *PIK3CA*    *SS18\**    *USP6*                     
  *CIC*             *EWSR1\**   *GRB7*      *MGEA5*     *NRG1*       *PLAGI*     *STAT6\**   *YWHAE*                    
  *COL6A3*          *FGFR1*     *HMGA2*     *MKL2*      *NTRK1\**    *PPARG*     *TAF15\**                              
  *DNAJB1*          *FGFR2\**   *JAK3*      *MYB*       *NTRK2*      *PRKACA*    *TCF12*                                
  ----------------- ----------- ----------- ----------- ------------ ----------- ----------- ------------ ------------- -------------

\*Clinically validated genes.

Briefly, RNA was extracted from tumor FFPE material followed by cDNA synthesis, cDNA end repair, dA tailing, and ligation with Illumina molecular barcode adapters. SPRI-cleaned ligated fragments are subject to two rounds of PCR amplifications using two sets of gene-specific primers (GSP1 used in PCR1 and a nested GSP2 pool that is 3′ downstream from GSP1 and used in PCR2) and a primer complementary to the Illumina adapter. At the end of two PCR steps, the final targeted amplicons were sequenced on an Illumina MiSeq instrument (2 × 150 bp). The Archer analysis software V5.0 was used for data analysis, which revealed no evidence of oncogenic gene fusions in the tumor sample.

ADDITIONAL INFORMATION {#s6}
======================
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--------------------------

The *HIST1H3B* K36I variant described in the manuscript will be deposited in ClinVar (<https://www.ncbi.nlm.nih.gov/clinvar/>) under accession number SCV000993417. Raw sequencing data was not deposited because consent for public deposition of the genomic data was not granted.
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